Platinum Investment Management Ltd. lifted its position in Immatics (NASDAQ:IMTX - Free Report) by 53.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 311,722 shares of the company's stock after buying an additional 108,108 shares during the period. Platinum Investment Management Ltd. owned about 0.26% of Immatics worth $2,216,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Immatics in the third quarter worth about $114,000. Quarry LP raised its holdings in Immatics by 29.4% during the 3rd quarter. Quarry LP now owns 11,000 shares of the company's stock worth $126,000 after buying an additional 2,500 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Immatics in the fourth quarter valued at approximately $211,000. Point72 Asset Management L.P. acquired a new position in shares of Immatics in the third quarter valued at approximately $298,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Immatics by 9.3% during the third quarter. The Manufacturers Life Insurance Company now owns 164,766 shares of the company's stock worth $1,880,000 after acquiring an additional 13,997 shares in the last quarter. Institutional investors and hedge funds own 64.41% of the company's stock.
Immatics Trading Down 5.7 %
Shares of NASDAQ IMTX traded down $0.30 during midday trading on Friday, reaching $5.00. The company's stock had a trading volume of 516,803 shares, compared to its average volume of 594,767. Immatics has a fifty-two week low of $4.06 and a fifty-two week high of $13.77. The stock has a 50 day simple moving average of $5.06 and a 200-day simple moving average of $7.70. The stock has a market capitalization of $596.78 million, a price-to-earnings ratio of -7.58 and a beta of 0.83.
Analysts Set New Price Targets
Separately, The Goldman Sachs Group raised shares of Immatics to a "strong-buy" rating in a research note on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Immatics presently has an average rating of "Buy" and an average target price of $16.67.
Read Our Latest Research Report on IMTX
About Immatics
(
Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Further Reading
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
